LBA46Phase II study comparing pembrolizumab (PEM) with intermittent/short‐term dual MAPK pathway inhibition plus PEM in patients harboring the BRAFV600 mutation (IMPemBra)E A Rozeman,K Sikorska,L Grijpink-Ongering,B C Heeres,B A van de Wiel,A Sari,H Mallo,S Adriaansz,W Uyterlinde,J Lijnsvelt,L M Pronk,J B A G Haanen,J W B de Groot,S Wilgenhof,M A Vollenbergh,J V van Thienen,C U BlankAnnals of Oncology（2018）引用 7|浏览23暂无评分AI 理解论文溯源树样例生成溯源树，研究论文发展脉络Chat Paper正在生成论文摘要
